BioSpace News Archive

argenx SE (Euronext & Nasdaq: ARGX), today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

The enhanced knowledge that certain diseases are caused by the inheritance of single functionally defective gene has laid the idea of gene therapy.

Company poised to transform drug development and personalised healthcare in 2022, following series of key pharma partnerships leveraging its leading genomics platform and global real-world data access network.

OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), today announced that Margaret Dalesandro, Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi, M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair.

Bayer Consumer Health Division announced today its clinical research study, “Analgesic efficacy of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial” was published online in the Postgraduate Medicine journal.

Antengene Corporation Limited (the “Company” or “Antengene”) is pleased to announce that ATG-010 (selinexor, brand name: XPOVIO®), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound has received conditional approval for marketing by the National Medical Products Administration (the “NMPA”).

Thubrikar Aortic Valve, Inc., announced today that it received approval from a Competent Authority in Poland to conduct initial patient implants with its Optimum Transcatheter Aortic Valve Implantation (TAVI) system™.

According to Emergen Research, the global antibody services market size was USD 1.41 Billion in 2020 and is expected to reach USD 3.30 Billion in 2028 and register a revenue CAGR of 11.1% during the forecast period, 2021-2028.

According to Emergen Research, the global flow imaging microscopy market size was USD 31.9 Million in 2020 and is expected to reach USD 56 Million in 2028 and register a revenue CAGR of 7.2% during the forecast period, 2021-2028.

According to Emergen Research, the global organs-on-chips market size was USD 27.5 Million in 2020 and is expected to reach USD 209.4 Million in 2028 and register a revenue CAGR of 28.1% during the forecast period, 2021-2028.